Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Kappa Agonist on Hot Flashes in Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy women 45-60 years of age; 12 months amenorrhea~2. Documentation of \> 8 moderate to severe, daily hot flashes during one week of baseline monitoring using daily diaries~3. Availability of a family member or friend to drive participant home following clinic visits~Exclusion Criteria:~1. Use of hormonal prescription medication or supplements for vasomotor symptoms (VMS)~2. Use of narcotics~3. Use of SSRI (selective serotonin reuptake inhibitor)/SNRI (serotonin-norepinephrine reuptake inhibitors), gabapentin, MAOI (monoamine oxidase inhibitor), anti-epileptics, sedatives~4. History of polycystic ovarian syndrome or hirsutism~5. Current history of depression~6. Any chronic or acute medical illnesses including renal, hepatic, pulmonary diseases, or seizures~7. Substance abuse~8. Severe corn allergy~9. Known allergic reaction to pentazocine or naloxone~10. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data~11. Hysterectomy~12. Use of anticholinergic medications~13. Lactating or pregnant

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Cornstarch, National Formulary
- Standard Dose Kappa Agonist (Type: EXPERIMENTAL): Pentazocine/Naloxone 50/0.5 mg
- Half Dose Kappa Agonist (Type: EXPERIMENTAL): Pentazocine/Naloxone 25/0.25 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).